A detailed history of Verition Fund Management LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 76,510 shares of XERS stock, worth $234,120. This represents 0.0% of its overall portfolio holdings.

Number of Shares
76,510
Previous 74,234 3.07%
Holding current value
$234,120
Previous $167,000 30.54%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.06 - $2.96 $4,688 - $6,736
2,276 Added 3.07%
76,510 $218,000
Q2 2024

Aug 14, 2024

BUY
$1.7 - $2.45 $126,197 - $181,873
74,234 New
74,234 $167,000
Q3 2023

Nov 14, 2023

SELL
$1.8 - $2.69 $22,154 - $33,108
-12,308 Reduced 33.26%
24,700 $45,000
Q2 2023

Aug 14, 2023

BUY
$1.82 - $2.98 $67,354 - $110,283
37,008 New
37,008 $96,000
Q2 2022

Aug 15, 2022

BUY
$1.48 - $2.64 $18,745 - $33,438
12,666 New
12,666 $20,000

Others Institutions Holding XERS

About Xeris Biopharma Holdings, Inc.


  • Ticker XERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,956,992
  • Market Cap $416M
  • Description
  • Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...
More about XERS
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.